Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
Br J Haematol
; 202(2): 284-288, 2023 07.
Article
em En
| MEDLINE
| ID: mdl-37183377
ABSTRACT
Myeloproliferative neoplasms in blastic phase (MPN-BP) have a dreadful prognosis. We report the characteristics and outcomes of five MPN-BP patients treated with a never-before-described combination of azacytidine and venetoclax (to control BP transformation), added to ruxolitinib (needed to control constitutional symptoms). Median age was 76 years (range 72-84), and worst performance status was 2. The overall response rate was 80%, and the complete remission rate was 40%. With median follow-up of 10.0 months (range 4.2-13.4), median overall survival was 13.4 months (95% CI 4.2-13.4). We did not detect any unexpected treatment-related toxicity, and quality of life was improved.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Azacitidina
/
Transtornos Mieloproliferativos
Tipo de estudo:
Prognostic_studies
Limite:
Aged
/
Aged80
/
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article